Cost-Effectiveness Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes and Established Cardiovascular Disease in Italy, Based on the Results of the EMPA-REG OUTCOME Study. FE 2017, 18 (1). https://doi.org/10.7175/fe.v18i1.1332.